These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 20025849)

  • 1. Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors.
    Reuveni D; Halperin D; Fabian I; Tsarfaty G; Askenasy N; Shalit I
    Biochem Pharmacol; 2010 Apr; 79(8):1100-7. PubMed ID: 20025849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinolones as enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I effects.
    Reuveni D; Halperin D; Shalit I; Priel E; Fabian I
    Biochem Pharmacol; 2008 Mar; 75(6):1272-81. PubMed ID: 18191106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line.
    Reuveni D; Halperin D; Shalit I; Priel E; Fabian I
    Int J Oncol; 2010 Aug; 37(2):463-71. PubMed ID: 20596674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxifloxacin enhances antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells.
    Fabian I; Reuveni D; Levitov A; Halperin D; Priel E; Shalit I
    Br J Cancer; 2006 Oct; 95(8):1038-46. PubMed ID: 17047652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
    Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
    Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines.
    Weiss T; Shalit I; Blau H; Werber S; Halperin D; Levitov A; Fabian I
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1974-82. PubMed ID: 15155187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-inflammatory effects of moxifloxacin on rat airway smooth muscle cells exposed to allergen: Inhibition of extracellular-signal-regulated kinase and nuclear factor-κB activation and of interleukin-8 and eotaxin synthesis.
    Li H; Zhu S; He S; Hao L
    Respirology; 2012 Aug; 17(6):997-1005. PubMed ID: 22616553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G; Goulette FA; Darnowski JW; Calabresi P
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis.
    Almeida D; Nuermberger E; Tyagi S; Bishai WR; Grosset J
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4261-6. PubMed ID: 17938193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
    Takahashi N; Haba A; Matsuno F; Seon BK
    Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
    Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
    Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
    Naka T; Sugamura K; Hylander BL; Widmer MB; Rustum YM; Repasky EA
    Cancer Res; 2002 Oct; 62(20):5800-6. PubMed ID: 12384541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.
    Yoshimatsu T; Nuermberger E; Tyagi S; Chaisson R; Bishai W; Grosset J
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1875-9. PubMed ID: 12019103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
    Matsuzaki T; Takagi A; Furuta T; Ueno S; Kurita A; Nohara G; Kodaira H; Sawada S; Hashimoto S
    Oncol Rep; 2012 Jan; 27(1):189-97. PubMed ID: 21935577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
    Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS
    Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib.
    Bocci G; Falcone A; Fioravanti A; Orlandi P; Di Paolo A; Fanelli G; Viacava P; Naccarato AG; Kerbel RS; Danesi R; Del Tacca M; Allegrini G
    Br J Cancer; 2008 May; 98(10):1619-29. PubMed ID: 18443598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of oral obligate anaerobes to telithromycin, moxifloxacin and a number of commonly used antibacterials.
    Tomás I; Tomás M; Alvarez M; Velasco D; Potel C; Limeres J; Diz P
    Oral Microbiol Immunol; 2007 Oct; 22(5):298-303. PubMed ID: 17803626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.
    Gliniak B; Le T
    Cancer Res; 1999 Dec; 59(24):6153-8. PubMed ID: 10626806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.